The speakers highlighted how combining these powerful drugs into fixed-duration regimens could help patients achieve long-term remissions and move closer to a cure.

The panel discussed combining trispecifics with mezigdomide, noting the strong activity and improved tolerability of targeting BCMA and CD38. They also discussed how mezigdomide might reverse T-cell exhaustion, while cautioning that careful treatment sequencing is necessary because mezigdomide is highly immune-activating.